A New Combinatorial Bispecific Protein that Selectively Binds HER2 and HER3 Receptors

View at publisher Summarise with VIRAT
Authors: I.V. Shulcheva, M. I. Kobyakova, V.V. Farofanova, D. O. Epiktetov, M. P. Shevelyova, A. B. Ulitin, A. S. Kazakov
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cancer is one of the most socially significant diseases of the 21st century. Since the advent of Paul Ehrlich's "magic bullet" concept, the idea of targeted cancer therapy has captivated researchers around the world. The most successful drugs in this niche are antibody-drug conjugates, however, they also have a number of limitations in their use. Peptide-cytotoxic agent conjugates have become a new class of drugs. They have a number of advantages, including small size, ease of production, and distribution in tumor tissues. This paper describes the process of cloning, expression, purification, and characterization of a bispecific protein targeting HER2 and HER3 receptors, which are key targets in breast cancer therapy. As a result of the work carried out, a recombinant protein with a high interaction constant with the HER2 receptor, as well as serum albumin, was obtained. The presence of specificity to albumin provides additional properties to a potential drug based on it, namely, an increased level of circulation in the bloodstream. Based on the results of cellular studies, it was shown that the drug effectively binds and internalizes into breast cancer cell lines with high surface coexpression of HER2 and HER3 receptors, which makes it potentially promising for therapy.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Toxin Mechanisms and Immunotoxins

Publication details

Journal / source
Биофизика / Biophysics
Volume
71
Issue
1
Pages
28–28
Publication date
1 January 2026
Language
EN